Skip to main content
SpringerLink
Log in

Thyroid Hormone and Cardiac Repair

  • Chapter
  • First Online:
Book cover Thyroid and Heart

  • 423 Accesses

Abstract

Thyroid hormone (TH) appears to play a critical role in cardiac repair after injury beyond its role in development and metabolism homeostasis. This unique action is due to the fact that TH effect on the heart is shown to be differentiated depending on its administration on injured or healthy myocardium. Thus, TH can limit ischemia-reperfusion injury via a fine balance between pro-apoptotic and pro-survival signaling pathways. This new evidence is consistent with clinical observations showing the cardioprotective effect of TH treatment in cardiac surgery, transplantation and heart failure. TH may be a novel therapeutic approach in treating heart diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:143–52.

    Article  PubMed  Google Scholar 

  2. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J. 2011;32:23–31.

    Article  CAS  PubMed  Google Scholar 

  3. Lee CH, Ju MH, Kim JB, Chung CH, Jung SH, Choo SJ, Lee JW. Myocardial injury following aortic valve replacement for severe aortic stenosis: risk factor of postoperative myocardial injury and its impact on long-term outcomes. Korean J Thorac Cardiovasc Surg. 2014;47:233–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Springeling T, Kirschbaum SW, Rossi A, Baks T, Karamermer Y, Schulz C, Ouhlous M, Duncker DJ, Moelker A, Krestin GP, Serruys PW, de Feyter P, van Geuns RJ. Late cardiac remodeling after primary percutaneous coronary intervention-five-year cardiac magnetic resonance imaging follow-up. Circ J. 2012;77:81–8.

    Article  PubMed  Google Scholar 

  5. Alameddine AK, Visintainer P, Normand SL, Wolf RE, Alameddine YA. Cancer rates in adults after cardiac interventions: a preliminary observational report. Am J Clin Oncol. 2017;40(2):122–4.

    Article  PubMed  Google Scholar 

  6. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006;82:1396–401.

    Article  CAS  PubMed  Google Scholar 

  7. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406–11.

    Article  CAS  PubMed  Google Scholar 

  8. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, Antoniucci D. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106:2351–7.

    Article  PubMed  Google Scholar 

  9. Mourouzis I, Politi E, Pantos C. Thyroid hormone and tissue repair: new tricks for an old hormone? J Thyroid Res. 2013;2013:312104.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Pantos C, Mourouzis I, Cokkinos DV. Thyroid hormone and cardiac repair/regeneration: from Prometheus myth to reality? Can J Physiol Pharmacol. 2012;90:977–87.

    Article  CAS  PubMed  Google Scholar 

  11. De Groot LJ. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Crit Care Clin. 2006;22:57–86. vi

    Google Scholar 

  12. Lazzeri C, Sori A, Picariello C, Chiostri M, Gensini GF, Valente S. Nonthyroidal illness syndrome in ST-elevation myocardial infarction treated with mechanical revascularization. Int J Cardiol. 2012;158:103–4.

    Article  PubMed  Google Scholar 

  13. Stathatos N, Levetan C, Burman KD, Wartofsky L. The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab. 2001;15:465–78.

    Article  CAS  PubMed  Google Scholar 

  14. Lymvaios I, Mourouzis I, Cokkinos DV, Dimopoulos MA, Toumanidis ST, Pantos C. Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association? Eur J Endocrinol. 2011;165:107–14.

    Article  CAS  PubMed  Google Scholar 

  15. Chuang CP, Jong YS, Wu CY, Lo HM. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure. Am J Cardiol. 2014;113:845–50.

    Article  CAS  PubMed  Google Scholar 

  16. Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118:132–6.

    Article  CAS  PubMed  Google Scholar 

  17. Fontana M, Passino C, Poletti R, Zyw L, Prontera C, Scarlattini M, Clerico A, Emdin M, Iervasi G. Low triiodothyronine and exercise capacity in heart failure. Int J Cardiol. 2012;154:153–7.

    Article  PubMed  Google Scholar 

  18. Pantos C, Dritsas A, Mourouzis I, Dimopoulos A, Karatasakis G, Athanassopoulos G, Mavrogeni S, Manginas A, Cokkinos DV. Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. Eur J Endocrinol. 2007;157:515–20.

    Article  CAS  PubMed  Google Scholar 

  19. Selvaraj S, Klein I, Danzi S, Akhter N, Bonow RO, Shah SJ. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:234–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kaptein EM, Sanchez A, Beale E, Chan LS. Clinical review: thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis. J Clin Endocrinol Metab. 2010;95:4526–34.

    Article  CAS  PubMed  Google Scholar 

  21. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, Keogh BE, Mascaro J, Riddington DW, Rooney SJ, Townend JN, Wilson IC, Bonser RS. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation. 2006;114:I245–50.

    PubMed  Google Scholar 

  22. Sirlak M, Yazicioglu L, Inan MB, Eryilmaz S, Tasoz R, Aral A, Ozyurda U. Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg. 2004;26:720–5.

    Article  PubMed  Google Scholar 

  23. Macdonald PS, Aneman A, Bhonagiri D, Jones D, O'Callaghan G, Silvester W, Watson A, Dobb G. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. Crit Care Med. 2012;40:1635–44.

    Article  CAS  PubMed  Google Scholar 

  24. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid. 1997;7:139–45.

    Article  CAS  PubMed  Google Scholar 

  25. Novitzky D, Cooper DK. Thyroid hormones and the stunned myocardium. J Endocrinol. 2014;223(1):R1–8.

    Article  CAS  PubMed  Google Scholar 

  26. Novitzky D, Mi Z, Sun Q, Collins J, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective review. Transplantation. 2014;98:1119–27.

    Article  CAS  PubMed  Google Scholar 

  27. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998;81:443–7.

    Article  CAS  PubMed  Google Scholar 

  28. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med. 1996;101:461–7.

    Article  CAS  PubMed  Google Scholar 

  29. Moruzzi P, Doria E, Agostoni PG, Capacchione V, Sganzerla P. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:374–8.

    Article  CAS  PubMed  Google Scholar 

  30. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'Abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:1351–8.

    CAS  PubMed  Google Scholar 

  31. Pantos C, Mourouzis I, Cokkinos DV. Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling. Vasc Pharmacol. 2010;52:157–65.

    Article  CAS  Google Scholar 

  32. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D. Thyroid hormone and “cardiac metamorphosis”: potential therapeutic implications. Pharmacol Ther. 2008;118:277–94.

    Article  CAS  PubMed  Google Scholar 

  33. Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Moraitis P, Tzeis S, Paizis I, Cokkinos AD, Carageorgiou H, Varonos DD, Cokkinos DV. Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur J Pharmacol. 2003;478:53–60.

    Article  CAS  PubMed  Google Scholar 

  34. Pantos C, Malliopoulou V, Mourouzis I, Thempeyioti A, Paizis I, Dimopoulos A, Saranteas T, Xinaris C, Cokkinos DV. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res. 2006;38:308–13.

    Article  CAS  PubMed  Google Scholar 

  35. Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem. 2003;242:173–80.

    Article  CAS  PubMed  Google Scholar 

  36. Pantos C, Mourouzis I, Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail Rev. 2011;16:79–96.

    Article  CAS  PubMed  Google Scholar 

  37. Pantos C, Mourouzis I, Saranteas T, Brozou V, Galanopoulos G, Kostopanagiotou G, Cokkinos DV. Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRalpha1 receptor. Mol Cell Biochem. 2011;353:235–41.

    Article  CAS  PubMed  Google Scholar 

  38. Pantos C, Mourouzis I, Saranteas T, Clave G, Ligeret H, Noack-Fraissignes P, Renard PY, Massonneau M, Perimenis P, Spanou D, Kostopanagiotou G, Cokkinos DV. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res Cardiol. 2009;104:69–77.

    Article  CAS  PubMed  Google Scholar 

  39. Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM. Short term triiodo-l-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol. 2008;44:180–7.

    Article  CAS  PubMed  Google Scholar 

  40. Forini F, Kusmic C, Nicolini G, Mariani L, Zucchi R, Matteucci M, Iervasi G, Pitto L. Triiodothyronine prevents cardiac ischemia/reperfusion mitochondrial impairment and cell loss by regulating miR30a/p53 axis. Endocrinology. 2014;155(11):4581–90.

    Article  PubMed  CAS  Google Scholar 

  41. Pantos CI, Malliopoulou VA, Mourouzis IS, Karamanoli EP, Paizis IA, Steimberg N, Varonos DD, Cokkinos DV. Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning. Thyroid. 2002;12:325–9.

    Article  CAS  PubMed  Google Scholar 

  42. Pantos CI, Malliopoulou VA, Mourouzis IS, Karamanoli EP, Tzeis SM, Carageorgiou HC, Varonos DD, Cokkinos DV. Long-term thyroxine administration increases heat stress protein-70 mRNA expression and attenuates p38 MAP kinase activity in response to ischaemia. J Endocrinol. 2001;170:207–15.

    Article  CAS  PubMed  Google Scholar 

  43. Kapoor MC. Phenylephrine in cardiac surgery: will it have a place? Ann Card Anaesth. 2014;17:209–10.

    PubMed  Google Scholar 

  44. Mourouzis I, Saranteas T, Ligeret H, Portal C, Perimenis P, Pantos C. Phenylephrine postconditioning increases myocardial injury: are alpha-1 sympathomimetic agonist cardioprotective? Ann Card Anaesth. 2014;17:200–9.

    Article  PubMed  Google Scholar 

  45. Pantos C, Mourouzis I, Tzeis S, Moraitis P, Malliopoulou V, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos D. Dobutamine administration exacerbates postischaemic myocardial dysfunction in isolated rat hearts: an effect reversed by thyroxine pretreatment. Eur J Pharmacol. 2003;460:155–61.

    Article  CAS  PubMed  Google Scholar 

  46. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191–8.

    Article  CAS  PubMed  Google Scholar 

  47. Sato T, Sato H, Oguchi T, Fukushima H, Carvalho G, Lattermann R, Matsukawa T, Schricker T. Insulin preconditioning elevates p-Akt and cardiac contractility after reperfusion in the isolated ischemic rat heart. Biomed Res Int. 2014;2014:536510.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Pantos C, Mourouzis I, Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail Rev. 2010;16:79–96.

    Article  CAS  Google Scholar 

  49. Pantos C, Mourouzis I, Cokkinos DV. Rebuilding the post-infarcted myocardium by activating ‘physiologic’ hypertrophic signaling pathways: the thyroid hormone paradigm. Heart Fail Rev. 2010;15:143–54.

    Article  CAS  PubMed  Google Scholar 

  50. Kalofoutis C, Mourouzis I, Galanopoulos G, Dimopoulos A, Perimenis P, Spanou D, Cokkinos DV, Singh J, Pantos C. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. Mol Cell Biochem. 2010;345:161–9.

    Article  CAS  PubMed  Google Scholar 

  51. Mourouzis I, Giagourta I, Galanopoulos G, Mantzouratou P, Kostakou E, Kokkinos AD, Tentolouris N, Pantos C. Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: a response associated with up-regulation of Akt/mTOR and AMPK activation. Metabolism. 2013;62:1387–93.

    Article  CAS  PubMed  Google Scholar 

  52. Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Roukounakis N, Kokkinos AD, Cokkinos DV, Pantos C. Dose dependent effects of thyroid hormone on post-ischaemic cardiac performance: potential involvement of Akt and ERK signaling. Mol Cell Biochem. 2012;363:235–43.

    Article  CAS  PubMed  Google Scholar 

  53. Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD, Panagiotou M, Cokkinos DV. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg. 2007;32:333–9.

    Article  PubMed  Google Scholar 

  54. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol. 2008;103:308–18.

    Article  CAS  PubMed  Google Scholar 

  55. Pantos C, Mourouzis I, Tsagoulis N, Markakis K, Galanopoulos G, Roukounakis N, Perimenis P, Liappas A, Cokkinos DV. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J Physiol Pharmacol. 2009;60:49–56.

    CAS  PubMed  Google Scholar 

  56. Ma L, Kerr BA, Naga Prasad SV, Byzova TV, Somanath PR. Differential effects of Akt1 signaling on short- versus long-term consequences of myocardial infarction and reperfusion injury. Lab Investig. 2014;94(10):1083–91.

    Article  CAS  PubMed  Google Scholar 

  57. Sallin EA. Fiber orientation and ejection fraction in the human left ventricle. Biophys J. 1969;9:954–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765–75.

    Article  CAS  PubMed  Google Scholar 

  59. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20:736–44.

    Article  CAS  PubMed  Google Scholar 

  60. Howell NJ, Ashrafian H, Drury NE, Ranasinghe AM, Contractor H, Isackson H, Calvert M, Williams LK, Freemantle N, Quinn DW, Green D, Frenneaux M, Bonser RS, Mascaro JG, Graham TR, Rooney SJ, Wilson IC, Pagano D. Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial. Circulation. 2011;123:170–7.

    Article  CAS  PubMed  Google Scholar 

  61. Ji L, Zhang X, Liu W, Huang Q, Yang W, Fu F, Ma H, Su H, Wang H, Wang J, Zhang H, Gao F. AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PLoS One. 2013;8:e69910.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Pantos C, Xinaris C, Mourouzis I, Malliopoulou V, Kardami E, Cokkinos DV. Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling? Mol Cell Biochem. 2007;297:65–72.

    Article  CAS  PubMed  Google Scholar 

  63. Naqvi N, Li M, Calvert JW, Tejada T, Lambert JP, Wu J, Kesteven SH, Holman SR, Matsuda T, Lovelock JD, Howard WW, Iismaa SE, Chan AY, Crawford BH, Wagner MB, Martin DI, Lefer DJ, Graham RM, Husain A. A proliferative burst during preadolescence establishes the final cardiomyocyte number. Cell. 2014;157:795–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Li M, Iismaa SE, Naqvi N, Nicks A, Husain A, Graham RM. Thyroid hormone action in postnatal heart development. Stem Cell Res. 2014;13(3 Pt B):582–91.

    Article  CAS  PubMed  Google Scholar 

  65. Pantos C, Xinaris C, Mourouzis I, Perimenis P, Politi E, Spanou D, Cokkinos DV. Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"? J Physiol Pharmacol. 2008;59:253–69.

    CAS  PubMed  Google Scholar 

  66. van der Heide SM, Joosten BJ, Dragt BS, Everts ME, Klaren PH. A physiological role for glucuronidated thyroid hormones: preferential uptake by H9c2(2-1) myotubes. Mol Cell Endocrinol. 2007;264:109–17.

    Article  PubMed  CAS  Google Scholar 

  67. van der Putten HH, Joosten BJ, Klaren PH, Everts ME. Uptake of tri-iodothyronine and thyroxine in myoblasts and myotubes of the embryonic heart cell line H9c2(2-1). J Endocrinol. 2002;175:587–96.

    Article  PubMed  Google Scholar 

  68. Hellen N, Wheeler J, Pinto Riccardo C, Foldes G, Kodagoda T, Whiting G, Mioulane M, Terracciano C, Vauchez K, Harding S. Effect of T3 on human induced pluripotent stem cell-derived cardiomyocyte maturation. Cardiovasc Res. 2014;103:S62.

    Article  Google Scholar 

  69. Ivashchenko CY, Pipes GC, Lozinskaya IM, Lin Z, Xiaoping X, Needle S, Grygielko ET, Hu E, Toomey JR, Lepore JJ, Willette RN. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. Am J Physiol Heart Circ Physiol. 2013;305:H913–22.

    Article  CAS  PubMed  Google Scholar 

  70. Liappas A, Mourouzis I, Zisakis A, Economou K, Lea R-W, Pantos C. Cell type dependent thyroid hormone effects on glioma tumor cell lines. J Thyroid Res. 2011:856050.

    Google Scholar 

  71. Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2011;38:359–67.

    Article  PubMed  CAS  Google Scholar 

  72. Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD, D’Alessandro A, Dec GW, Edwards NM, Higgins RS, Jeevanandum V, Kauffman M, Kirklin JK, Large SR, Marelli D, Peterson TS, Ring WS, Robbins RC, Russell SD, Taylor DO, Van Bakel A, Wallwork J, Young JB. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation. 2002;106:836–41.

    Article  PubMed  Google Scholar 

  73. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122:385–93.

    Article  PubMed  Google Scholar 

  74. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer DC, Baumgartner C, Blum MR, Browne JP, Byrne S, Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW, Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G, McCarthy V, McConnachie A, McDade M, Messow M, O'Flynn A, O'Riordan D, Poortvliet RKE, Quinn TJ, Russell A, Sinnott C, Smit JWA, Van Dorland HA, Walsh KA, Walsh EK, Watt T, Wilson R, Gussekloo J, TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):2534–44.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, National and Kapodistrian University of Athens, Athens, Greece

    Constantinos Pantos

Authors
  1. Constantinos Pantos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constantinos Pantos .

Editor information

Editors and Affiliations

  1. Institute of Clinical Physiology (IFC) National Research Council (CNR), Pisa, Italy

    Giorgio Iervasi

  2. Institute of Clinical Physiology (IFC) National Research Council (CNR), Pisa, Italy

    Alessandro Pingitore

  3. NYITCOM College of Osteopathic Medicine Biomedical Sciences Department, Old Westbury, NY, USA

    A.Martin Gerdes

  4. Institute of Clinical and Translational Medicine, Newcastle University/Queen Elizabeth Hospital, Newcastle upon Tyne, UK

    Salman Razvi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pantos, C. (2020). Thyroid Hormone and Cardiac Repair. In: Iervasi, G., Pingitore, A., Gerdes, A., Razvi, S. (eds) Thyroid and Heart . Springer, Cham. https://doi.org/10.1007/978-3-030-36871-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36871-5_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36870-8

  • Online ISBN: 978-3-030-36871-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation